Introduction
============

The Li population, which is one among the 55 minority ethnic groups in the People's Republic of China, exceeds 1.3 million and resides primarily in the Li and Miao Autonomous Prefecture in the center and southwest regions of the Hainan Province. However, a small number of the Li population members are intermixed with the Han people. Among the male Li villagers, the prevalence rates of tobacco users (84.1% were lifetime smokers) and (92.5% were lifetime drinkers) are higher than those of the national average and other ethnic minorities in People's Republic of China, but fewer Li females reported smoking (1.9% were lifetime smokers) or alcohol consumption (21.0% were lifetime drinkers).[@b1-copd-10-1455]

Chronic obstructive pulmonary disease (COPD) is defined as airflow limitation that is not completely reversible. COPD is typically caused by exposure to noxious particles or gases, predominantly cigarette smoking; however, other exposures such as biomass fuels are an important cause worldwide.[@b2-copd-10-1455] In fact, COPD is one of the leading causes of morbidity and mortality worldwide[@b3-copd-10-1455],[@b4-copd-10-1455] and is expected to be the third leading cause of worldwide mortality and the fifth leading cause of morbidity by the year 2020.[@b4-copd-10-1455]

Both genetic and environmental factors contribute to the disease etiology of COPD, and substantial evidence suggests that a genetic susceptibility to COPD exists.[@b5-copd-10-1455] Recently, the application of genome-wide association studies (GWAS) has enabled the identification of a number of common variants involved in the etiology of COPD. In large studies including subjects with a range of smoking histories and damaged lung function, GWAS results have revealed genomic regions that demonstrate a highly and reproducible association with COPD. The regions are located in family with sequence similarity 13, member A (*FAM13A*) on chromosome 4q22,[@b6-copd-10-1455] and near hedgehog interacting protein (*HHIP*) on chromosome 4q31.[@b7-copd-10-1455] One prior GWAS involving 2,940 cases and 1,380 smoking controls with normal lung function identified common genetic risk variants in *FAM13A* \[rs7671167, odds ratio (OR) =0.76, combined *P*=1.2×10^−11^\], and provided evidence of replication in one case--control and two family-based cohorts in Norway.[@b6-copd-10-1455] Other studies of *HHIP*, which encode an inhibitory protein for sonic hedgehog, revealed that single nucleotide polymorphisms (SNPs) upstream of *HHIP* both modulate the expression of *HHIP* and functionally link reduced HHIP expression to COPD pathogenesis,[@b8-copd-10-1455] and are crucial for the development of the lungs and other organs.[@b9-copd-10-1455] Additional studies identified three SNPs on *HHIP* (rs13118928, rs13141641, and rs1828591) that were associated with COPD and lung function in non-Asian populations.[@b7-copd-10-1455],[@b10-copd-10-1455],[@b11-copd-10-1455] Recently, the association of *HHIP* polymorphisms with COPD and COPD-related phenotypes has been found in Chinese Han population.[@b3-copd-10-1455] A separate association study suggested that the genetic predisposition to COPD and to lung cancer could share common pathogenetic factors including the 4q22.1 locus, which implicating the Rho-kinase pathway.[@b12-copd-10-1455] It is well known that smoking is associated with lung cancer; thus, we selected candidate SNPs (rs950063, rs17050782, and rs10007052) between *FAM13A* and *HHIP* from chromosome 4 that are reportedly associated with cigarette smoking behaviors.[@b13-copd-10-1455],[@b14-copd-10-1455] Vascular endothelial growth factor A (*VEGFA*), which is located on chromosome 6p21.1, is an important gene that encodes protein with potent angiogenic properties that enhances vascular permeability and modulates thrombogenicity. The biological properties of *VEGFA* have led to interest in its role within the lung in both healthy and diseased states.[@b15-copd-10-1455] In fact, studies involving lung tissue obtained from patients with COPD have suggested that the expression of *VEGFA* may play a role in the pathogenesis of the disease.[@b16-copd-10-1455],[@b17-copd-10-1455] As well, a previous study suggested that *VEGFA* may be an important factor in both chronic lung and cardiovascular disease processes, and could link COPD with cardiovascular disorders.[@b18-copd-10-1455]

Previous COPD association studies have focused on the Chinese Han nationality and other large groups, but specific data on the Li population are lacking. Because of the various genetic backgrounds among different nationalities, one aim of this study was to verify whether COPD susceptibility loci from *VEGFA* and the genetic risk variants in *FAM13A* and *HHIP* identified in prior GWAS were significant in the Chinese Li minority population. The second objective was to try to find new *FAM13A* and *HHIP* susceptibility loci for COPD among smoking behaviors in Chinese Li minority individuals. To this end, we anticipated that we could successfully identify suitable and accurate molecular markers of COPD among the Chinese Li minority population.

Materials and methods
=====================

Study participants
------------------

The Chinese Li minority population-based case--control study comprising COPD patients diagnosed from January 2010 to December 2013 from the Hainan Province People's Hospital was conducted. All subjects were Chinese Li minority individuals identified from the ID card information. All cases were diagnosed by a physician based on a COPD pulmonary function test (PFT) indicating a post-bronchodilator (post-BD) forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) of less than 70% and the FEV~1~ of less than 80% predicted, and disease severity was classified according to the global initiative for chronic obstructive lung disease criteria.[@b19-copd-10-1455] Patients were excluded from the study if they had an established diagnosis of asthma, lung cancer, a history of atopy, or a known α1-antitrypsin deficiency before PFT.[@b3-copd-10-1455] A total of 1,734 subjects from the department of respiratory underwent PFT during this study period at the Hainan Province People's Hospital. We also excluded 50 patients whose age was \<40 and who did not complete the questionnaires. Among the remaining 1,684 patients, 421 had a pre-BD FEV~1~/FVC of \<0.7. We excluded 153 patients who did not undergo post-BD spirometry. Among the remaining 268 patients, 34 had a post-BD FEV~1~/FVC of ≥0.7 and FEV~1~ of more than 80% predicted. Eventually, 234 patients consisted of 142 males and 92 females were found to have COPD with a post-BD FEV~1~/FVC of \<0.7 ([Figure 1](#f1-copd-10-1455){ref-type="fig"}). Control subjects were randomly recruited from the health centers of Hainan Province Hospital during the same period. Exclusion criteria were as described for cases and additionally included family history of COPD. Finally, 240 controls consisting of 151 males and 89 females with a mean age of 62.09 years, who were at least 40 years old, and in good mental health were recruited in this study. Detailed population information for the study participants is shown in [Table 1](#t1-copd-10-1455){ref-type="table"}.

Spirometry and calculated method
--------------------------------

COPD is defined as a post-BD FEV~1~/FVC ratio of \<0.7 in patients aged ≥40 years, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline.[@b20-copd-10-1455] Spirometry results were expressed as percentages of the predicted values and were calculated using Morris's predictive equations as follows: predicted FEV~1~ for men =0.092× height −0.032× age −1.26, predicted FEV~1~ for women =0.089× height −0.025× age −1.932 (height in inches).[@b21-copd-10-1455]

Spirometry was performed using spirometers (models: VMAX229, VMAX22, and VMAX20; SensorMedics, Yorba Linda, CA, USA) by trained technicians according to the 2005 American Thoracic Society/European Respiratory Society recommendations.[@b22-copd-10-1455],[@b23-copd-10-1455]

Demographic and clinical data
-----------------------------

To obtain the basic research data, demographic and personal information were collected through the use of a standardized questionnaire that included smoking history status (we defined never smokers as individuals who had smoked less than 100 cigarettes during their lifetime), weight, body mass index \[BMI = weight (kg)/height (m^2^)\], and special examinations including electrocardiogram, pulmonary function, and color sonography. Each procedure was conducted by the same professionals, and the questionnaire survey staff was methodically trained to ensure strict quality control of the administration of the questionnaire during the investigation, and ensured all participants signed on the questionnaire. The case information was collected through consultation with the treating physicians or by reviewing the medical chart. Written informed consent was obtained from all subjects, and the study was approved by the ethics committee of Hainan Province People's Hospital.

SNP selection and genotyping
----------------------------

Targeted reuse of existing GWAS data is a reported approach for identifying additional putative risk alleles.[@b24-copd-10-1455] Accordingly, one SNP (rs7671167) was chosen from *FAM13A* and three SNPs (rs1828591, rs13118928, and rs13141641) were chosen from *HHIP*. All of the selected SNPs were in the region of chromosome 4q and were associated with COPD and COPD-related phenotypes in non-Asian populations according to recent GWAS,[@b6-copd-10-1455],[@b7-copd-10-1455],[@b10-copd-10-1455],[@b11-copd-10-1455] and were subsequently verified in Chinese Han populations.[@b3-copd-10-1455] Three SNPs (rs950063, rs17050782, and rs10007052) located in the region of chromosome 4q between *FAM13A* and *HHIP* were all in the region of chromosome 4q and were selected based on reported associations with cigarette smoking behaviors.[@b13-copd-10-1455],[@b14-copd-10-1455] Nine SNPs (rs25648, rs833068, rs833070, rs3024994, rs3024997, rs3025000, rs3025030, rs3025033, and rs10434) located in *VEGFA* in the region of chromosome 6p21.1 that indicated both chronic lung and cardiovascular disease processes were selected, because *VEGFA* may be an important factor linking COPD with cardiovascular disease.[@b17-copd-10-1455],[@b18-copd-10-1455] Ultimately, we obtained 16 SNPs in different genes that were in Hardy--Weinberg equilibrium (HWE; *P*-value \>0.05) in the control individuals. We extracted genomic DNA from peripheral blood using a GoldMag^®^ -- Mini Whole Blood Genomic DNA Purification Kit (GoldMag^®^ Ltd., Xi'an, People's Republic of China) according to the manufacturer's protocol, and DNA concentrations were measured using a NanoDrop™ 2000C (Thermo Fisher Scientific, Waltham, MA, USA). We used the Sequenom Mass-ARRAY^®^ Assay Design 3.0 software (Sequenom, Inc., San Diego, CA, USA) to design Multiplexed SNP Mass-EXTEND assays.[@b25-copd-10-1455] SNP genotyping was performed using the standard protocol recommended by the manufacturer with a Sequenom Mass-ARRAY^®^ RS1000 (Sequenom, Inc.). Sequenom Typer 4.0 software was used for data management and analyses.[@b26-copd-10-1455]

Statistical analyses
--------------------

We used the SPSS 21.0 statistical packages (SPSS Inc., Chicago, IL, USA) and Microsoft Excel for statistical analysis. All *P*-values in this study were two sided, and *P*=0.05 was considered the threshold for statistical significance. The validation of each SNP frequency in control subjects was tested for departure from HWE using an exact test. Allele frequencies and genotype frequencies for each SNP of COPD patients and control subjects were compared using a chi-squared (*χ*^2^) test.[@b27-copd-10-1455] Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic-regression analysis with adjustments for age, sex, and smoking status.[@b28-copd-10-1455] We evaluated whether an interaction existed between covariate smoking status (smoking or non-smoking) and each SNP loci using logistic-regression models (recessive, dominant, and codominant models). We calculated the linkage disequilibrium (LD) coefficients and constructed haplotype using the Haploview software package (version 4.2) (Mark Daly's Laboratory, Massachusetts Institute of Technology/Harvard Broad Institute, Cambridge, MA, USA).[@b29-copd-10-1455] We used SNP Stats (Catalan Institute of Oncology, Barcelona, Spain), a web-based software to test the associations between certain SNPs and the risk of COPD in five genetic models (dominant, codominant, overdominant, recessive, and log-additive).[@b30-copd-10-1455]

Results
=======

A total of 474 Li participants, including 234 COPD cases and 240 controls, were successfully genotyped for further analysis. Males represented 62.9% of the controls and 60.7% of the cases. Fewer females than males participated in this study. However, sex was equally distributed among COPD cases and control subjects. There was a significant difference between the cases and controls in terms of mean age distribution (67.52 in cases vs 62.09 in controls *P*\<0.001; [Table 1](#t1-copd-10-1455){ref-type="table"}). [Table 2](#t2-copd-10-1455){ref-type="table"} summarizes the basic characteristics of the SNPs in the study population, and shows that all 16 SNPs conformed to HWE in the controls (*P*\>0.05). We compared the differences in frequency distributions of alleles between cases and controls by Pearson *χ*^2^ test and found only the minor allele "G" in rs17050782 from SET domain containing protein 7 (*SETD7*) was significantly associated with risk of COPD in the study population (*P*=0.014, OR=1.40, 95% CI=1.07--1.83).

We also used SNP Stats to assess the association between these SNPs and COPD risks using five genetic models (codominant, dominant, recessive, overdominant, and log-additive) by unconditional logistic-regression analysis. As shown in [Table 3](#t3-copd-10-1455){ref-type="table"}, crude analysis revealed the genotype "G/G" in rs17050782 was associated with increased risk of COPD under the codominant model (*P*=0.007, OR=2.64, 95% CI=1.40--5.00), under the recessive model (*P*=0.002, OR=2.52, 95% CI=1.38--4.61), and under log-additive model (*P*=0.012, OR=1.42, 95% CI=1.08--1.87). After adjustment for sex, age, and smoking status, we found two SNPs, rs7671167 located in *FAM13A* and rs17050782 located in *SETD7*, were associated with increased COPD risk. The genotypes "T/C" and "T/T" in rs7671167 from *FAM13A* were associated with increased COPD risk (*P*=0.028, OR=1.58, 95% CI=1.05--2.38) under the dominant model, whereas the genotype "G/G" in rs17050782 from *SETD7* was associated with increased COPD risk under the codominant model (*P*=0.026, OR=2.41, 95% CI=1.24--4.69), under the recessive model (*P*=0.008, OR=2.30, 95% CI=1.22--4.31), and under the log-additive model (*P*=0.03, OR=1.38, 95% CI=1.03--1.85) ([Table 4](#t4-copd-10-1455){ref-type="table"}). Perhaps due to the genetic differences between the Li population and other large populations or because of the small sample size, we did not identify any associations between SNPs located in *HHIP* and COPD in Chinese Li minority population included in this study.

One haplotype block that included two SNPs (rs1828591 and rs13118928) with *D*′=1 ([Figure 2](#f2-copd-10-1455){ref-type="fig"}) was detected in *HHIP* SNPs by haplotype analyses. Haplotypes with frequencies \>1% were selected for analysis, and the association between inferred haplotypes and COPD risk among the individuals was analyzed. However, we found no association between the selected haplotype and COPD risk. Two haplotype blocks that included five SNPs (rs833068, rs833070, rs3024994, rs3024997, and rs3025000) with *D*′=1 ([Figure 3](#f3-copd-10-1455){ref-type="fig"}) were detected in *VEGFA* SNPs by haplotype analyses. The five SNPs constructed four haplotypes ("AGCAT", "GACGC", "GGCGC", and "GGTGC"), and the haplotype "GGCGC" in the *VEGFA* gene was significantly associated with increased risk of COPD under the logistic-regression model adjusted for sex, age, and smoking status (OR=1.48, 95% CI=1.02--2.12, *P*=0.037). The results of the association between the *VEGFA* haplotype and the risk of COPD are listed in [Table 5](#t5-copd-10-1455){ref-type="table"}. Another haplotype block that included two SNPs (rs3025030 and rs3025033) is shown in [Figure 3](#f3-copd-10-1455){ref-type="fig"}, but the haplotypes were not found to be associated with COPD risk.

Discussion
==========

In this case--control study that included an ample number of COPD cases and controls (234 cases and 240 controls) from the Chinese Li minority population, we determined that the rs7671167 SNP from *FAM13A* (adjusted *P*-value =0.028 under the dominant model) and the rs17050782 SNP from *SETD7* (adjusted *P*-value =0.008 under the recessive model) were associated with an increased risk of COPD. Likewise, we observed that the haplotype "GGCGC" in *VEGFA* was associated with an increased risk of developing COPD (OR=1.48, 95% CI=1.02--2.12, *P*=0.037) under the logistic-regression model adjusted for sex, age, and smoking status.

COPD is an escalating global health problem caused by multiple genetic and environmental factors.[@b5-copd-10-1455] Further, even if the same genetic variant was involved in each population, the LD relationships of this variant with neighboring genetic polymorphisms would likely vary between ethnic groups. The rs7671167 SNP, which was first described by Cho et al, is located in intron 4 of *FAM13A* and is in LD with SNPs in the Rho-GTPase activating proteins domain region.[@b6-copd-10-1455] Previous studies have confirmed that in Caucasians, the *FAM13A* rs7671167 variant confers a protective effect on smoking-related COPD alone (C allele, OR=0.79, *P*=0.013; and CC genotype, OR=0.71, *P*=0.024) and on COPD, both with and without lung cancer (C allele, OR=0.80, *P*=0.008; and CC genotype, OR=0.70, *P*=0.007).[@b12-copd-10-1455] In this study, we also confirmed that the association of the rs7671167 loci with COPD, but we studied a different ethnic group; our results indicated that the minor allele "T" in rs7671167 was associated with increased COPD risk (*P*=0.028, OR=1.58, 95% CI=1.05--2.38) under the dominant model (T/C, T/T, vs CC).

To date, the biological function of the rs7671167 SNP located in *FAM13A* has not been fully characterized.[@b6-copd-10-1455] However, prior studies have reported that *FAM13A* is an interesting candidate gene because of the Rho-GTPase activating proteins domain it encodes,[@b31-copd-10-1455] and because of its associated tumor suppressor activity via inhibition of the intracellular signal transduction molecule Rho-A.[@b32-copd-10-1455] In the present study, we also discovered a new SNP (rs17050782) located in *SETD7* code super antigen-like protein 5 that was associated with increased risk of COPD under the recessive model (*P*=0.008, OR=2.30, 95% CI=1.22--4.31). Previous study mentioned that the SNP (rs17050782) was predicted with cigarette smoking behaviors from the GWAS (*P*\<10^−5^) but did not verified coding regions associated with cigarette smoking behaviors.[@b14-copd-10-1455] *VEGF* is a potent mediator of angiogenesis that has multiple effects on lung development and physiology. As well, previous studies have suggested the up-regulation of systemic inflammation and circulating *VEGF* levels in patients with acute exacerbated COPD.[@b18-copd-10-1455] Although our findings indicated that no associations existed between SNPs in *VEGFA* and COPD, which was not in accord with the results of previous studies, we observed that the haplotype "GGCGC" in *VEGFA* was associated with increased risk of COPD under the logistic-regression model adjusted for sex, age, and smoking status (OR=1.48, 95% CI=1.02--2.12, *P*=0.037).

The present study had several limitations. First, despite our ability to identify genetic associations with COPD, we were not able to elucidate causal mechanisms. Nonetheless, despite the limitations of our small sample size, we were still able to demonstrate several associations with COPD.[@b33-copd-10-1455] However, a larger sample size and a greater number of loci might have allowed for additional evidence regarding the role of these genes in COPD. Second, we did not account for the effects of secondhand smoke or other smoke in the "no smoking" individuals. Hence, our future research should incorporate the analysis of the relationship between COPD and detailed smoking status including smoking intensity, secondhand smoking, and air smog. Finally, considering the marked difference in smoking prevalence among sex, which is an established risk factor for COPD, sex differences could exist. However, because the sample size was not large enough, we did not attempt separate analysis for males or females and other stratified analyses. However, if analyzed in-depth, these study data could provide important clues regarding COPD pathogenesis, especially given the fact that we determined the rs7671167 SNP with "T" allele was associated with enhanced risk of COPD, in contrast to the already published study that reported the rs7671167 SNP with a "C" allele demonstrated a protective effect.

In summary, we are the first to identify two candidate loci (rs7671167 and rs17050782) associated with increased risk of COPD in the Chinese Li minority population. As well, we are the first to report that the "GGCGC" haplotype in the *VEGFA* was associated with an increased risk of developing COPD. However, we are aware that prior to using these loci and haplotype as molecular markers for the detection and prevention of COPD, further studies are required to elucidate the functional variants that confer a risk for COPD in the associated genomic regions.
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![The flow diagram of COPD subjects selected in this study.\
**Note:** All subjects were Chinese Li minority population.\
**Abbreviations:** BD, bronchodilator; FEV~1~/FVC, forced expiratory volume in 1 second/forced vital capacity; COPD, chronic obstructive pulmonary disease.](copd-10-1455Fig1){#f1-copd-10-1455}

![Linkage disequilibrium (LD) plots containing three single nucleotide polymorphisms (SNPs) from the 4q21.1 to 4q31.21.\
**Notes:** LD analysis of the *HHIP* in Chinese Li controls. LD is indicated using standard color schemes with bright red signifying very strong LD (LOD ≥2, *D*′=1).\
**Abbreviation:** LOD, likelihood of odds.](copd-10-1455Fig2){#f2-copd-10-1455}

![Linkage disequilibrium (LD) plots containing nine SNPs from the *VEGFA*.\
**Notes:** LD analysis of *VEGFA* in Chinese Li controls. LD is indicated using standard color schemes with bright red signifying very strong LD (LOD ≥2, *D*′=1), pink red signifying relatively weak LD (LOD ≥2, *D*′,1).\
**Abbreviations:** LOD, likelihood of odds; SNP, single nucleotide polymorphism.](copd-10-1455Fig3){#f3-copd-10-1455}

###### 

Characteristics of study cases and controls

  Characteristic           Case (N=234)   Control (N=240)   *P*-value
  ------------------------ -------------- ----------------- -----------------------------------------------------
  Sex, no (%)                                               0.617[a](#tfn2-copd-10-1455){ref-type="table-fn"}
   Male                    142 (60.7)     151 (62.9)        
   Female                  92 (39.3)      89 (37.1)         
  Smoking status, no (%)                                    0.162[b](#tfn3-copd-10-1455){ref-type="table-fn"}
   Nonsmoking              141 (60.3)     160 (66.7)        
   Smoking                 90 (38.5)      78 (32.5)         
   Missing                 3 (1.3)        2 (0.8)           
  Mean age ± SD            67.52±9.19     62.09±11.44       \<0.001[b](#tfn3-copd-10-1455){ref-type="table-fn"}

**Notes:** *P*\<0.05 indicates statistical significance;

for Pearson's *χ*^2^ test;

for Welch's *t*-test.

**Abbreviation:** SD, standard deviation.

###### 

Information on the 16 SNPs in this study

  SNPs         Chr       Position    Gene        A/B   HWE-*P*   OR     95% CI       Allele, *P*-value[a](#tfn5-copd-10-1455){ref-type="table-fn"}   *P*-value[b](#tfn6-copd-10-1455){ref-type="table-fn"}
  ------------ --------- ----------- ----------- ----- --------- ------ ------------ --------------------------------------------------------------- -------------------------------------------------------
  rs7671167    4q22.1    89883979    *FAM13A*    T/C   0.502     1.19   0.92--1.54   0.187                                                           1
  rs950063     4q28.1    126431919   *MIR2054*   C/T   0.057     0.92   0.68--1.24   0.586                                                           1
  rs17050782   4q31.1    140423134   *SETD7*     G/A   0.070     1.40   1.07--1.83   0.014[c](#tfn7-copd-10-1455){ref-type="table-fn"}               0.224
  rs10007052   4q31.21   142005573   *RNF150*    C/A   0.248     0.75   0.52--1.08   0.120                                                           1
  rs1828591    4q31.21   145480780   *HHIP*      G/A   0.444     1.03   0.78--1.35   0.862                                                           1
  rs13118928   4q31.21   145486389   *HHIP*      G/A   0.277     1.05   0.79--1.38   0.743                                                           1
  rs13141641   4q31.21   145506456   *HHIP*      C/T   0.375     1.04   0.79--1.36   0.788                                                           1
  rs25648      6p21.1    43738977    *VEGFA*     T/C   0.568     1.63   0.63--4.23   0.521                                                           1
  rs833068     6p21.1    43742527    *VEGFA*     A/G   1         0.83   0.47--1.46   0.213                                                           1
  rs833070     6p21.1    43742626    *VEGFA*     A/G   0.145     0.84   0.63--1.11   0.884                                                           1
  rs3024994    6p21.1    43743507    *VEGFA*     T/C   0.481     1.02   0.77--1.36   0.113                                                           1
  rs3024997    6p21.1    43745107    *VEGFA*     A/G   0.880     0.75   0.52--1.08   0.208                                                           1
  rs3025000    6p21.1    43746169    *VEGFA*     T/C   1         0.84   0.63--1.11   0.210                                                           1
  rs3025030    6p21.1    43750587    *VEGFA*     C/G   0.593     0.84   0.63--1.11   0.272                                                           1
  rs3025033    6p21.1    43751075    *VEGFA*     G/A   0.592     1.22   0.86--1.73   0.248                                                           1
  rs10434      6p21.1    43753212    *VEGFA*     A/G   0.122     1.23   0.85--1.75   0.867                                                           1

**Notes:**

*P*-value was calculated using two-sided *χ*^2^ tests;

*P*-value was adjusted by Bonferroni correction;

*P*\<0.05 indicates statistical significance.

**Abbreviations:** Chr, chromosomes; A/B, minor/major allele; HWE, Hardy--Weinberg equilibrium; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Association of rs17050782 with COPD in cases and controls

  Model          Genotype   Control[a](#tfn9-copd-10-1455){ref-type="table-fn"}   Case[a](#tfn9-copd-10-1455){ref-type="table-fn"}   OR (95% CI)         *P*-value                                            AIC     BIC
  -------------- ---------- ----------------------------------------------------- -------------------------------------------------- ------------------- ---------------------------------------------------- ------- -------
  Codominant     A/A        104 (44.1%)                                           88 (37.9%)                                         1                   0.007[b](#tfn10-copd-10-1455){ref-type="table-fn"}   644.9   657.3
                 A/G        115 (48.7%)                                           106 (45.7%)                                        1.09 (0.74--1.61)                                                                
                 G/G        17 (7.2%)                                             38 (16.4%)                                         2.64 (1.40--5.00)                                                                
  Dominant       A/A        104 (44.1%)                                           88 (37.9%)                                         1                   0.18                                                 650.9   659.2
                 A/G-G/G    132 (55.9%)                                           144 (62.1%)                                        1.29 (0.89--1.87)                                                                
  Recessive      A/A-A/G    219 (92.8%)                                           194 (83.6%)                                        1                   0.002[b](#tfn10-copd-10-1455){ref-type="table-fn"}   643     651.3
                 G/G        17 (7.2%)                                             38 (16.4%)                                         2.52 (1.38--4.61)                                                                
  Overdominant   A/A-G/G    121 (51.3%)                                           126 (54.3%)                                        1                   0.51                                                 652.3   660.6
                 A/G        115 (48.7%)                                           106 (45.7%)                                        0.89 (0.62--1.27)                                                                
  Log-additive   --         --                                                    --                                                 1.42 (1.08--1.87)   0.012[b](#tfn10-copd-10-1455){ref-type="table-fn"}   646.5   654.8

**Notes:**

n=468, crude analysis;

*P*\<0.05 indicates statistical significance.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; AIC, Akaike's information criterion; BIC, Bayesian information criterion.

###### 

Association of rs7671167 and rs17050782 with COPD in cases and controls

  SNP          Model          Genotype   Control[a](#tfn12-copd-10-1455){ref-type="table-fn"}   Case[a](#tfn12-copd-10-1455){ref-type="table-fn"}   OR (95% CI)         *P*-value
  ------------ -------------- ---------- ------------------------------------------------------ --------------------------------------------------- ------------------- ----------------------------------------------------
                              C/C        87 (36.5%)                                             68 (29.4%)                                          1                   
               Codominant     T/C        110 (46.2%)                                            120 (52%)                                           1.58 (1.02--2.43)   0.088
                              T/T        41 (17.2%)                                             43 (18.6%)                                          1.59 (0.91--2.79)   
               Dominant       C/C        87 (36.5%)                                             68 (29.4%)                                          1                   0.028[b](#tfn13-copd-10-1455){ref-type="table-fn"}
                              T/C-T/T    151 (63.5%)                                            163 (70.6%)                                         1.58 (1.05--2.38)   
  rs7671167                                                                                                                                                             
                              C/C-T/C    197 (82.8%)                                            188 (81.4%)                                         1                   
               Recessive                                                                                                                                                0.45
                              T/T        41 (17.2%)                                             43 (18.6%)                                          1.21 (0.74--1.98)   
                              C/C-T/T    128 (53.8%)                                            111 (48%)                                           1                   
               Overdominant                                                                                                                                             0.14
                              T/C        110 (46.2%)                                            120 (52%)                                           1.33 (0.91--1.95)   
               Log-additive   --         --                                                     --                                                  1.30 (0.99--1.72)   0.057
               Co-dominant    A/G        114 (48.7%)                                            106 (46.3%)                                         1.09 (0.72--1.64)   0.026[b](#tfn13-copd-10-1455){ref-type="table-fn"}
                              G/G        17 (7.3%)                                              37 (16.2%)                                          2.41 (1.24--4.69)   
               Dominant       A/A        103 (44%)                                              86 (37.5%)                                          1                   0.23
  rs17050782                  A/G-G/G    131 (56%)                                              143 (62.5%)                                         1.27 (0.86--1.87)   
               Recessive      A/A-A/G    217 (92.7%)                                            192 (83.8%)                                         1                   0.008[b](#tfn13-copd-10-1455){ref-type="table-fn"}
                              G/G        17 (7.3%)                                              37 (16.2%)                                          2.30 (1.22--4.31)   
               Overdominant   A/A-G/G    120 (51.3%)                                            123 (53.7%)                                         1                   0.6
                              A/G        114 (48.7%)                                            106 (46.3%)                                         0.90 (0.61--1.32)   
               Log-additive   ---        ---                                                    ---                                                 1.38 (1.03--1.85)   0.03[b](#tfn13-copd-10-1455){ref-type="table-fn"}

**Notes:**

n=469, adjusted for sex, age, and smoking status;

*P*\<0.05 indicates statistical significance.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Five SNPs in *VEGFA* haplotypes and risk of COPD adjusted for sex, age, and smoking status

  rs833068   rs833070   rs3024994   rs3024997   rs3025000   Frequency   OR (95% CI)         *P*-value
  ---------- ---------- ----------- ----------- ----------- ----------- ------------------- ----------------------------------------------------
  A          G          C           A           T           0.29        1                   --
  G          A          C           G           C           0.28        1.11 (0.78--1.59)   0.57
  G          G          C           G           C           0.28        1.48 (1.02--2.12)   0.037[a](#tfn15-copd-10-1455){ref-type="table-fn"}
  G          G          T           G           C           0.15        0.88 (0.57--1.37)   0.58

**Note:**

*P*\<0.05 indicates statistical significance.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

[^1]: These authors contributed equally to this work
